Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$734.57 +0.3%	$747.03	$623.78 ▼ $969.65	$693.36B	0.47	6.61 million shs	3.22 million shs
MCD McDonald's	$315.53 +0.6%	$302.18	$276.53 ▼ $326.32	$223.74B	0.5	3.21 million shs	3.23 million shs
NVO Novo Nordisk A/S	$56.37 -0.2%	$60.17	$45.05 ▼ $138.62	$252.09B	0.66	18.14 million shs	11.61 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	0.00%	+5.22%	-3.82%	-2.47%	-23.71%
MCD McDonald's	0.00%	+0.16%	+3.57%	+0.32%	+8.67%
NVO Novo Nordisk A/S	0.00%	+0.28%	+17.16%	-20.30%	-59.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LLY Eli Lilly and Company	5 of 5 stars	4.3	3.0	3.3	4.0	2.6	3.3	3.8
MCD McDonald's	4.4675 of 5 stars	2.2	3.0	4.2	1.1	2.7	2.5	2.5
NVO Novo Nordisk A/S	4.336 of 5 stars	4.1	3.0	2.5	0.0	2.6	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LLY Eli Lilly and Company	2.67	Moderate Buy	$950.17	29.35% Upside
MCD McDonald's	2.38	Hold	$326.38	3.44% Upside
NVO Novo Nordisk A/S	2.13	Hold	$81.00	43.70% Upside

Current Analyst Ratings Breakdown

Latest MCD, NVO, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/22/2025	MCD McDonald's	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$300.00 ➝ $315.00
8/22/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2025	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/19/2025	NVO Novo Nordisk A/S	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$105.00 ➝ $70.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00
8/13/2025	NVO Novo Nordisk A/S	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LLY Eli Lilly and Company	$45.04B	15.44	$14.27 per share	51.47	$19.39 per share	37.88
MCD McDonald's	$25.92B	8.69	$14.83 per share	21.28	($3.87) per share	-81.53
NVO Novo Nordisk A/S	$42.12B	5.98	$3.90 per share	14.47	$5.73 per share	9.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LLY Eli Lilly and Company	$10.59B	$15.30	48.01	23.60	1.02	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
MCD McDonald's	$8.22B	$11.67	27.04	23.80	3.19	32.21%	-225.52%	15.07%	11/4/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	15.49	12.10	1.96	35.60%	78.64%	24.51%	11/5/2025 (Estimated)

Latest MCD, NVO, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	MCD McDonald's	$3.15	$3.19	+$0.04	$3.14	$6.68 billion	$6.84 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LLY Eli Lilly and Company	$6.00	0.82%	N/A	39.22%	11 Years
MCD McDonald's	$7.08	2.24%	N/A	60.67%	49 Years
NVO Novo Nordisk A/S	$0.82	1.45%	N/A	22.53%	N/A

Latest MCD, NVO, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MCD McDonald's	quarterly	$1.77	2.24%	9/2/2025	9/2/2025	9/16/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LLY Eli Lilly and Company	1.86	1.28	1.00
MCD McDonald's	N/A	1.30	1.29
NVO Novo Nordisk A/S	0.52	0.78	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LLY Eli Lilly and Company	82.53%
MCD McDonald's	70.29%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
LLY Eli Lilly and Company	0.14%
MCD McDonald's	0.25%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
MCD McDonald's	150,000	713.60 million	711.82 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable

MCD, NVO, and LLY Headlines

Recent News About These Companies

Investors who lost money on Novo Nordisk A/S (NVO) should contact Levi & Korsinsky about pending Class Action - NVO

September 2 at 3:51 PM | globenewswire.com

Novo Nordisk is undervalued, this fund manager says

September 2 at 12:22 PM | cantechletter.comC

NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S ...

September 2 at 12:22 PM | bakersfield.comB

Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

September 2 at 12:00 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

September 2 at 10:00 AM | globenewswire.com

What Makes Novo Nordisk A/S (NVO) an Attractive Investment Compared to Competitors?

September 2 at 9:51 AM | insidermonkey.com

What Makes Novo Nordisk A/S (NVO) an Attractive Investment Compared to Competitors?

September 2 at 9:51 AM | finance.yahoo.com

NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

September 2 at 9:44 AM | globenewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders

September 2 at 8:45 AM | prnewswire.com

Novo Nordisk A/S (NVO) Wins U.S. Wegovy Approval for MASH, Expands to China Market

September 2 at 7:22 AM | finance.yahoo.com

Unisphere Establishment Sells 118,500 Shares of Novo Nordisk A/S $NVO

September 2 at 6:50 AM | marketbeat.com

Phasecraft Raises $34 Million from Plural, Playground Global, and Novo Holdings to Bring Quantum Computing Closer to Solving Real-World Challenges

September 2 at 5:00 AM | businesswire.com

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

September 2 at 2:16 AM | prnewswire.com

Rep. Marjorie Taylor Greene Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

September 2 at 2:02 AM | marketbeat.com

Novo Nordisk (NVO) Jumps as Wegovy Beats Eli Lilly in Cardiovascular Outcomes

September 1 at 4:19 PM | finance.yahoo.com

NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

September 1 at 4:00 PM | globenewswire.com

NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?

September 1 at 11:56 AM | zacks.com

Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes

September 1 at 9:05 AM | cnbc.com

Armistice Capital LLC Has $7.50 Million Holdings in Novo Nordisk A/S $NVO

September 1 at 8:13 AM | marketbeat.com

Novo Nordisk's Wegovy Raises European Shares Amidst Trade Tensions

September 1 at 6:45 AM | devdiscourse.comD

European Shares Rise Amid Novo Nordisk's Heart-Health Drug Success

September 1 at 6:45 AM | devdiscourse.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MCD, NVO, and LLY Company Descriptions

Eli Lilly and Company NYSE:LLY

$734.57 +1.99 (+0.27%)

Closing price 03:59 PM Eastern

Extended Trading

$733.80 -0.77 (-0.10%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

McDonald's NYSE:MCD

$315.53 +1.99 (+0.63%)

Closing price 03:59 PM Eastern

Extended Trading

$315.48 -0.05 (-0.01%)

As of 07:59 PM Eastern

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

Novo Nordisk A/S NYSE:NVO

$56.37 -0.09 (-0.16%)

Closing price 03:59 PM Eastern

Extended Trading

$56.39 +0.02 (+0.04%)

As of 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time